BIOHARVEST SCIENCES INC. 2022 CEO LETTER TO SHAREHOLDER PARTNERS 2022 / Sam Chaloub BIOHARVEST SCIENCES INC. 2022 CEO LETTER TO SHAREHOLDER PARTNERS Read More »
BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE THIRD TRANCHE OF CONVERTIBLE NOTES 2022 / Sam Chaloub BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE THIRD TRANCHE OF CONVERTIBLE NOTES Read More »
BIOHARVEST SCIENCES INC. PROJECTS 2023 REVENUE TO GROW 3.0X-3.5X TO A RANGE OF USD $17M-$20M 2022 / Sam Chaloub BIOHARVEST SCIENCES INC. PROJECTS 2023 REVENUE TO GROW 3.0X-3.5X TO A RANGE OF USD $17M-$20M Read More »
ROYAL EMERALD PHARMACEUTICALS PARTNERS WITH BIOHARVEST SCIENCES TO SUPPLY DISRUPTIVE CANNABIS SOLUTIONS TO COMPANIES CONDUCTING FDA-APPROVED MEDICAL RESEARCH 2022, Uncategorized / Sam Chaloub ROYAL EMERALD PHARMACEUTICALS PARTNERS WITH BIOHARVEST SCIENCES TO SUPPLY DISRUPTIVE CANNABIS SOLUTIONS TO COMPANIES CONDUCTING FDA-APPROVED MEDICAL RESEARCH Read More »
BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT OF CONVERTIBLE NOTES AND EXPECTS THE OFFERING TO BE OVERSUBSCRIBED AND TO CLOSE AN ADDITIONAL TRANCHE OF UP TO $3 MILLION BY DECEMBER 15, 2022 2022 / Sam Chaloub BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT OF CONVERTIBLE NOTES AND EXPECTS THE OFFERING TO BE OVERSUBSCRIBED AND TO CLOSE AN ADDITIONAL TRANCHE OF UP TO $3 MILLION BY DECEMBER 15, 2022 Read More »
BIOHARVEST INTRODUCES ITS 1ST CANNABIS BREAKTHROUGH COMPOSITION WITH MAJOR MEDICAL AND COMMERCIAL IMPLICATIONS 2022 / Sam Chaloub BIOHARVEST INTRODUCES ITS 1ST CANNABIS BREAKTHROUGH COMPOSITION WITH MAJOR MEDICAL AND COMMERCIAL IMPLICATIONS Read More »
